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The less mucoid strain of Brucella cams or M- strain is 
used for the serologic diagnosis of canine brucellosis. 
While this strain is avirulent in dogs, we report the case of 
clinical brucellosis that developed in a laboratory worker a 
few days after handling live M- cells for antigen production.
Tyrucella canis is the causative agent of canine brucel- 
Y>losis, which causes contagious abortion, orchiepi­
didymitis. and uveitis. Transmission to human requires 
close contact with infected animals or bacterial cultures. 
Symptomatic human infections are rare, probably because 
of the low virulence of B. canis', 31 human cases have been 
reported (1).
In contrast to other Brucella species, which are patho­
genic for humans (B. abortus, B. melitensis, B. suis) and 
yield smooth colonies, B. canis colonies are naturally 
rough. Therefore, serologic tests that use suspensions of 
smooth brucellae are not useful in diagnosing B. canis 
infections (2). Since suspensions of wild-type B. canis tend 
to aggregate even in the absence of specific antibodies, a 
less mucoid variant termed M-, which does not produce 
autoagglutination is used for serologic diagnosis (3). The 
M- strain lias reduced virulence in dogs; even high doses 
of this strain do not induce the typical signs of brucellosis 
in dogs (4). The pathogenic potential of the M- strain in 
humans remains unknown, and to the best of our knowl­
edge, human infection by this strain has not been reported. 
We report a clinical and immunologic study of a human 
infection by the B. canis M- strain that shows that this 
strain can produce human disease similar to that produced 
by wild-type B. canis.
Case Report
A 3 5-year-old male laboratory worker was referred to a 
physician with recurrent fever, headache, arthralgia, weak­
ness, and constipation, which had begun 1 month before. 
The patient worked in a laboratory that produced antigens 
for diagnostic use. Three weeks before symptoms began, 
he had been handling a dense culture of live B. canis M-
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and was using no personal protection; the procedures were 
not performed in a biological safety cabinet. Moreover, the 
patient had attempted resuspension by repeated pipetting 
with his mouth. The clinical examination disclosed cervi­
cal adenomegaly, and laboratory tests indicated a mild 
increase of hepatic enzymes (Aspartate aminotransferase 
46 U/L and alanine aminotransferase 65 U/L) and neu­
tropenia. The patient reported not having close contact 
with dogs or other animals. Taking into account the unpro­
tected exposure to B. canis M-, brucellosis was suspected, 
and blood samples were drawn for culture and serologic 
studies. Two weeks later blood cultures indicated a 
Brucella species that was later typed as B. canis. 
Conventional tests for antibodies to smooth brucellae 
(agglutination, complement fixation) yielded negative 
results. In contrast, slide agglutination for B. canis was 
strongly positive with undiluted serum and was also posi­
tive at 1:10 dilution. Serologic tests for hepatotropic virus­
es and Toxoplasma gondii were negative.
After diagnosis, a course with oral doxycycline, 100 mg 
twice a day for 42 days, plus parenteral gentamicin, 180 
mg once a day for 10 days, was started. The patient clini­
cally recovered, but on the last day gentamicin was admin­
istered, symptoms of VIII cranial nerve involvement 
occurred, which resolved with fhmarizine and vitamin B12 
administration.
Blood cultures performed 2 weeks after antimicrobial 
therapy ended were negative for B. canis. During follow­
up, the patient remained asymptomatic, his cervical adeni­
tis resolved, and serum levels of hepatic enzymes returned 
to normal. On his last visit, 4 years after infection, the 
patient was asymptomatic. While he continues to handle B. 
canis M-, cultures are now performed under strict biologi­
cal safety measures (biological safety cabinet, personal 
protection including goggles, gloves and mask, and auto­
claving of contaminated material).
Immunologic Studies
To assess the humoral iimnune response of the patient 
to Brucella antigens, the slide agglutination test with B. 
canis M- and 3 enzyme-linked immunosorbent assays 
(ELISA) were used. ELISA used a hot-saline extract of B. 
canis M- (HS, mainly composed of rough lipopolysaccha­
ride [LPS] and outer membrane proteins), a preparation of 
cytoplasmic proteins of B. abortus depleted of LPS (CP 
[cytoplasmic proteins]) or recombinant Brucella lumazine 
synthase (RBLS), which were obtained as described previ­
ously (5-7). As shown in the Figure, antibodies to the three 
antigens were detected at the time of diagnosis, but anti­
bodies to proteinaceous antigens (CP and RBLS) were 
negative earlier than those against HS. The slide agglutina­
tion test that used B. canis M- and undiluted serum was 
strongly positive at diagnosis and 48 days later (beginning
146 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 1, January 2004
DISPATCHES
Days after diagnosis
—-CP —o—BLS —o—HS
Figure. Serological follow-up of a human infection by Brucella 
canis M-. CP, cytoplasmic proteins; BLS, Brucella lumazine syn­
thase; HS, B. canis hot-saline extract. The enzyme-linked 
immunosorbent assay (ELISA) titer was calculated as the inverse 
of the last serum dilution that yielded an optical density higher than 
the cut-off of the assay.
and end of therapy, respectively), weakly positive at 103 
and 150 days, and negative at 190 days and 4 years after 
diagnosis. Positive samples were assayed in serial dilu­
tions starting at 1:10; only the initial sample was positive 
at 1:10 dilution (negative at 1:20).
The cellular immune response against proteinaceous 
activity from Brucella in peripheral blood mononuclear 
cells (PBMCS) was also evaluated. In vitro proliferation 
and cytokine gene expression were investigated as previ­
ously described (8). For blastogenesis assays. PBMCS 
were cultured with CP (10 pg/mL), RBLS (5 pg/mL). or 
phytohemagglutinin (10 pg/mL). Results were expressed 
as stimulation index (counts per minute of stimulated cul­
tures divided by counts per minute of unstimulated cul­
tures). Stimulation indices (SI) >2 were considered posi­
tive. For reverse transcription-polymerase chain reaction 
(RT-PCR). RNA was extracted from PBMCS cultured in 
the presence of CP. RBLS. or phytohemagglutinin for 24 
hours. Results were expressed as fold increase over the 
messenger ribonucleic acid levels of cells cultured in the 
absence of antigen; increases >2 were considered specific.
CP and RBLS induced T-cell proliferation (SI >2) in 
PBMCS obtained from the patient before antimicrobial 
therapy (Table). PBMCS from a healthy person, which 
were run in parallel, showed no response to CP and RBLS 
(SI <2) (not shown). In addition, CP and RBLS induced a 
significant (p<0.001, nonparametric Mann-Whitney U 
test) upregulation of interferon-gamma (IFN-y), inter­
leukin (IL)-2, and IL-10 transcripts only in PBMCS from 
the patient. No IL-4 induction was observed with PBMCS 
from the patient or the healthy control (not shown). The 
cellular immune response declined with antimicrobial 
treatment (Table), but CP-specific IFN-y remained 
increased 55 days after therapy ended. In the last sample 
(obtained 250 days after therapy ended), all the parame­
ters of the cellular immune response were normal (not 
shown).
Conclusions
The main finding of our study is that the M- strain of B. 
canis can produce human disease, which was unexpected 
in view of the reported avirulent phenotype of this strain in 
dogs. To the best of our knowledge, this case is the first of 
human B. canis M- infection ever reported. The M- strain 
has been widely used for the diagnosis of canine brucel­
losis because it is less prone to autoagglutination than its 
wild-type counterpart (called M+). Based on the low viru­
lence of the M- strain in dogs (4), the production protocol 
of the laboratory where this case occurred did not include 
bacterial inactivation or personnel protection during initial 
handling of cultures, which led to a prolonged exposure to 
a high number of viable bacteria. As the patient was the 
only person involved in the production of this strain, his 
co-workers were not tested for B. canis M-. Similar illness 
in the production plant was not reported. Because Brucella 
spp. is not usually transmitted from patients to healthy per­
sons. the patient’s family members were not tested for B. 
canis M- infection.
The clinical manifestations in our patient were similar 
to those reported for human, wild-type B. canis infections 
(e.g.. fever, headache, anorexia, asthenia, and adenitis). 
Previous studies in dogs experimentally infected with the 
M- strain showed that this strain does not revert to the M+ 
phenotype in vivo (4). Our case may be analogous to cases 
of human illness by attenuated strains of Brucella species 
used for animal vaccination, mainly B. melitensis Rev-1 
(9) and B. abortus S19 (10). Altogether, these human 
infections indicate that attenuation for animals does not
Table. Cellular immune response in vitro to Brucella cytoplasmic proteins3
Antigen Lymphocyte proliferation (SI) IL-2b (fold increase) IFN-y1’ (fold increase) IL-10b (fold increase)
Before therapy BLS 4 8 3 3
CP 3 10 7 4.5
End of therapy BLS 1 1 2 1
CP 2.5 6 4 2
55 days after end BLS 1 1 1 1
of therapy CP 1 1 3 1
aBLS, Brucella lumazine synthase; CP, cytoplasmic proteins; SI, stimulation indices; IL, interleukin; IFN, interferon. 
’ By reverse transcription-polymerase chain reaction.
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necessarily mean innocuity for humans and that biological 
safety measures must be followed in each case.
To assess the humoral iimnune response to the infection 
with the M- strain, antibodies against outer membrane 
antigens (HS) and to internal antigens (CP and Brucella 
lumazine synthase) were measured. Overall, low titers of 
antibodies were found by all tests, which is similar to those 
found for M- infections in dogs (4). Low antibody titers 
also could be related to early administration of antimicro­
bial therapy, as has been shown in patients infected with 
smooth brucellae (11). Antibodies to both external and 
internal antigens declined after antimicrobial therapy was 
begun and were undetectable 6 months after diagnosis 
(Figure). This decline, with longer persistence of antibod­
ies to external antigens, is in agreement with our previous 
findings in human infections by smooth Brucella species 
(12).
An early and strong cellular Thl-type response to 
Brucella internal antigens developed in this patient, in 
agreement with our previous observations in acute human 
brucellosis (8). The reasons for the decline of this response 
during follow-up are unknown, but conceivably, bacteria 
levels were substantially diminished by the early antimi­
crobial therapy, thus eliminating the internal antigens 
needed to develop a long-lasting cellular immune 
response.
In summary, this case shows that, in spite of its reduced 
virulence in dogs, B. cams M- can produce human disease 
with a clinical picture similar to that produced by the infec­
tion with wild-type strains of B. cams. Therapeutic and 
immunologic parameters seem to be very similar to those 
observed in infections by smooth brucellae.
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